John Galivan
- Rheumatology top 1%
- Folate and B Vitamins Research 23
- Biochemistry top 1%
- Amino Acid Enzymes and Metabolism 22
- Hematology top 5%
- Chronic Myeloid Leukemia Treatments 11
- Molecular Biology top 5%
- Biochemical and Molecular Research 26
- Biopolymer Synthesis and Applications 21
-
- Acute Lymphoblastic Leukemia research 15
-
- Cancer Research and Treatments 13
-
- Liver Disease Diagnosis and Treatment 11
- Co-authors
- Myung S. RheeZenia NimecFrank MaleyGladys F. MaleyThomas J. RyanMałgorzata BalińskaKaren J. ChaveRong Yao
- Cited by
- RheumatologyBiochemistryHematology
- Journals
- Archives of Biochemistry and Biophysics (13 papers)Molecular Pharmacology (7 papers)Advances in experimental medicine and biology (6 papers)
- Partner nations
- United States
In The Last Decade
John Galivan
105 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 110
- Rheumatology 774
- Biochemistry 327
- Hematology 334
- Molecular Biology 1.4k
- Public Health, Environmental and Occupational Health 598
Countries citing papers authored by John Galivan
This map shows the geographic impact of John Galivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Galivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Galivan more than expected).
Fields of papers citing papers by John Galivan
This network shows the impact of papers produced by John Galivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Galivan. The network helps show where John Galivan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John Galivan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 62 | |
| 2 | 2000 | 69 | |
| 3 | 1999 | 30 | |
| 4 | 1997 | 42 | |
| 5 | Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. | 1996 | 2 |
| 6 | 1995 | 7 | |
| 7 | 1995 | 29 | |
| 8 | 1994 | 23 | |
| 9 | 1993 | 8 | |
| 10 | 1993 | 5 | |
| 11 | 1993 | 0 | |
| 12 | 1993 | 24 | |
| 13 | 1992 | 8 | |
| 14 | 1990 | 12 | |
| 15 | 1990 | 7 | |
| 16 | 1989 | 2 | |
| 17 | 1989 | 22 | |
| 18 | 1988 | 20 | |
| 19 | 1987 | 3 | |
| 20 | 1987 | 9 |
About John Galivan
John Galivan is a scholar working on Biochemistry, Rheumatology and Biotechnology, having authored 106 papers that have together received 2.6k indexed citations. Recurring topics across this work include Biochemical and Molecular Research (26 papers), Folate and B Vitamins Research (23 papers), Amino Acid Enzymes and Metabolism (22 papers), Biopolymer Synthesis and Applications (21 papers), Acute Lymphoblastic Leukemia research (15 papers), Cancer Research and Treatments (13 papers), Liver Disease Diagnosis and Treatment (11 papers) and Chronic Myeloid Leukemia Treatments (11 papers). The work is most often cited by research in Rheumatology (774 citations), Biochemistry (327 citations) and Hematology (334 citations). John Galivan has collaborated with scholars based in United States. Frequent co-authors include Myung S. Rhee, Zenia Nimec, Frank Maley, Gladys F. Maley, Thomas J. Ryan, Małgorzata Balińska, Karen J. Chave, Rong Yao, James K. Coward and Muraleedharan G. Nair. Their work appears in journals such as Archives of Biochemistry and Biophysics, Molecular Pharmacology, Advances in experimental medicine and biology, Journal of Medicinal Chemistry and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.